You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 54 No. 8, August 1997 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (22)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Double-blindness Procedures, Rater Blindness, and Ratings of Outcome

Observations From a Controlled Trial

Metin Basoglu, MD, PhD; Isaac Marks, MD, FRCPsych; Maria Livanou; Richard Swinson, MD, FRCPsych

Arch Gen Psychiatry. 1997;54(8):744-748.


Abstract



Background
We determined whether blindness in a double-blind randomized controlled trial of alprazolam and exposure therapies in patients with panic disorder and agoraphobia was maintained in assessors and patients, what were the factors related to "unblinding," and whether unblinding was associated with clinical outcome.

Method
In 129 patients with panic disorder and agoraphobia who were randomized to alprazolamexposure, placebo-exposure, alprazolam-relaxation, or placebo-relaxation conditions, blindness was tested at the end of treatment by the independent assessors' and patients' classification of the treatment condition.

Results
Assessors' classifications were correct in 82% of the alprazolam group and 78% of the placebo group; corresponding figures for patients' classifications were 73% and 70%, respectively. Factors associated with unblinding included drug side effects but not assessors' ratings of treatment outcome.

Conclusion
Judgment of the validity of the outcome of a randomized controlled trial is easier if the report notes not only the use of a double-blindness procedure but also details how blind the raters remained and how any unblinding affected their ratings of clinical outcome.



Author Affiliations



From the Section of Experimental Psychopathology, Department of Psychiatry, University of London, London, England (Drs Basoglu and Marks and Ms Livanou); and the Department of Psychiatry, Clark Institute of Psychiatry, Toronto, Ontario (Dr Swinson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

7.3 Understanding clinical trials in palliative care research
Farrar
Oxford Textbook of Palliative Medicine 2010;4:med-9780198570295-chapter-med-9780198570295-chapter.
ABSTRACT | FULL TEXT  

Blindness and Bias in a Trial of Antidepressant Medication For Chronic Tension-Type Headache
Holroyd et al.
Cephalalgia 2006;26:973-982.
ABSTRACT | FULL TEXT  

Is Acupuncture Analgesia an Expectancy Effect?: Preliminary Evidence Based on Participants' Perceived Assignments in Two Placebo-Controlled Trials
Bausell et al.
Eval Health Prof 2005;28:9-26.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.